Surgical Resection of Synchronously Metastatic Adrenocortical Cancer

Benzon M. Dy, Veljko Strajina, Ashley K. Cayo, Melanie L. Richards, David R. Farley, Clive S. Grant, William S. Harmsen, Doug B. Evans, Elizabeth G. Grubbs, Keith C. Bible, William F. Young, Nancy D. Perrier, Florencia G. Que, David M. Nagorney, Jeffrey E. Lee, Geoffrey B. Thompson

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Introduction: Metastatic adrenocortical carcinoma (ACC) is rapidly fatal, with few options for treatment. Patients with metachronous recurrence may benefit from surgical resection. The survival benefit in patients with hematogenous metastasis at initial presentation is unknown.

Methods: A review of all patients undergoing surgery (European Network for the Study of Adrenal Tumors) stage IV ACC between January 2000 and December 2012 from two referral centers was performed. Kaplan–Meier estimates were analyzed for disease-free and overall survival (OS).

Results: We identified 27 patients undergoing surgery for stage IV ACC. Metastases were present in the lung (19), liver (11), and brain (1). A complete resection (R0) was achieved in 11 patients. The median OS was improved in patients undergoing R0 versus R2 resection (860 vs. 390 days; p = 0.02). The 1- and 2-year OS was also improved in patients undergoing R0 versus R2 resection (69.9 %, 46.9 % vs. 53.0 %, 22.1 %; p = 0.02). Patients undergoing neoadjuvant therapy (eight patients) had a trend towards improved survival at 1, 2, and 5 years versus no neoadjuvant therapy (18 patients) [83.3 %, 62.5 %, 41.7 % vs. 56.8 %, 26.6 %, 8.9 %; p = 0.1]. Adjuvant therapy was associated with improved recurrence-free survival at 6 months and 1 year (67 %, 33 % vs. 40 %, 20 %; p = 0.04) but not improved OS (p = 0.63). Sex (p = 0.13), age (p = 0.95), and location of metastasis (lung, p = 0.51; liver, p = 0.67) did not correlate with OS after operative intervention. Symptoms of hormonal excess improved in 86 % of patients.

Conclusion: Operative intervention, especially when an R0 resection can be achieved, following systemic therapy may improve outcomes, including OS, in select patients with stage IV ACC. Response to neoadjuvant chemotherapy may be of use in defining which patients may benefit from surgical intervention. Adjuvant therapy was associated with decreased recurrence but did not improve OS.

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalAnnals of surgical oncology
Volume22
Issue number1
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Surgical Resection of Synchronously Metastatic Adrenocortical Cancer'. Together they form a unique fingerprint.

Cite this